WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Pharmacogenomics in Personalized medicine: A comprehensive review

Sakshi M. Chede[1], Rutuja G. Shelke[2], Dipali D. Birajdar[3], Sumit N. Patil[4], Mangesh U. Kunte[5]

[1]B pharmacy Final year student, Latur college of pharmacy, Hasegaon, SRTMUN
[2]Assistant professor, Latur college of pharmacy, Hasegaon, SRTMUN
[3]B pharmacy Final year student, Latur college of pharmacy, Hasegaon, SRTMUN
[4]B pharmacy Final year student, Latur college of pharmacy, Hasegaon, SRTMUN
[5]B pharmacy Final year student, Latur college of pharmacy, Hasegaon, SRTMUN

ABSTRACT :

The concept of personalized medicine, often referred to as precision medicine, embodies a paradigm shift in healthcare in which treatments and interventions are customized to an individual's genetic makeup, environment, and lifestyle. This shift from a one-size-fits-all model to a bespoke paradigm is expected to transform patient outcomes, improve care efficiency, and reduce costs. The development of genomics, proteomics, and health informatics has fueled the development of biomarker and treatment target identification, which has led to the concept of personalized medicine and diagnostics in various medicine specialties. However, widespread adoption of personalized medicine is hindered by privacy concerns, regulatory barriers, and lack of access to modern technology. Pharmacogenomics is a new concept in personalized medicine that relies on the selection and dosing of a drug or other therapeutic agents according to the patient's phenotype.

Key words: Personalized medicine, Pharmacogenomics, Pharmacokinetics, Pharmacodynamics, Cancer

Introduction:

The concept of personalized medicine focuses on tailoring specific procedures and treatments to each individual and, therefore, reflects an important transformation in healthcare. Through the application of contemporary technology like study of animal data, embodied cure proposes to change the way healthcare is provided by employing exact and specialized solutions. With wireless microphones and image software, the new automatic, extensive biomedical imaging techniques - proteomics and DNA sequencing, have buried multi-individual variation in the mechanisms and processes causing disease and its effects. There are different kinds of personalized medicine, but all of them have a common stone wall waiting for the approval of a regulatory body which makes it very difficult to pass through. Furthermore, skilled have numerous problems concerning the embodiment of cures from various collaboration health care corners such as physicians, health management executives, protection associations, and lastly, the patients. As many personalized or embodied medicaments, such as autologous CAR-T cell transplant therapies for certain cancers and ivacaftor for cystic fibrosis, are extremely harmful, a predominant portion of these issues focus on the need to demonstrate that embodied cure strategies truly outperform conventional treatment methodologies. This, as previously noted, seeks the advance of an individualized cure adapts therapeutic intervention to the unique features of the patient.



Pharmacogenomics :

Genomic data is used to analyze how an individual reacts to a drug in pharmacogenomics. A patient who possesses a gene variant linked to drug metabolism gives clinicians the opportunity to make prognostic decisions based on the patient's genetics in terms of adjusting the drug quantity or

possibly to change the drug entirely. Scientists study the gene variants which influence the reaction of any individual to a particular drug in the same manner as they investigate gene variants linked to diseases, that is, by searching for genetic loci marking the correlation with some known drug responses and checking out responders or nonresponders. In comparison to the more sophisticated approaches used in the study of populations, these techniques will be described as simpler. These methods are just beginning to be used clinically in areas such as drug target discovery and development: multigene analysis and whole genome single-nucleotide polymorphism (SNP) analysis.

Until now, pharmacogenomics has always guided tailor-made cures. Owing to the materialistic impacts on DNA expression, the Imperial College team headed by J.K. Nicholson has changed the traditional people's perception regarding this matter. The effect that juices, especially grapefruit juice, has on the plant CYP3A4 and later on the metabolic and pharmacodynamic properties of different medicines, drug interactions, and microbiota is well-known as a particular case. The enactment of the cure has now transcended the expl.

Fundamentals of Pharmacogenomics :

With regard to pharmacogenomics, genomic information is utilized for studying the response of a person with a given drug. When the gene changes have controls on the patient’s answer for the drug, they may be used to formulate genetically located situation decisions that is to some extent control the dosage or choose an alternative medication. Scientists expect genes that are supposed to affect how a person responds to a particular drug were historical mutations that guided an ailment: They identify genes that guide the popular drug responses and therefore test the ruling class in matters with unknown responses. Contemporary methods include polygenic reasoning or Genome-wide association studies (GWAS) which are SNP based and are believed to have been used previously in clinical practice for drug development.

Pharmacokinetics :

These types of interactions are called pharmacokinetic interactions, and they relate to the way a drug is taken in, distributed, metabolized, and eliminated from the body.
Certain features on a person’s genome may affect the activity of the drug instead of its effects on the body. For instance, genomic modifications may affect how much of a drug is made available at certain bioactive sites, which would thus affect the correct amount of medication that needs to be administered for the individual.

A good example is the cytokine metabolically active-protein 2D6, which is situated within a region responsible for the metabolism of many drugs. People with different CYP2D6 gene variants define a subset of rapid or slow metabolizers for certain drugs. For example, individuals who tend to rapidly metabolize drugs affected by CYP2D6, most often do not feel the effects as the drug is broken down and eliminated from the body quickly. On the other hand, slow metabolizers may experience improved efficacy from drugs, but may be more prone to side effects due to higher concentrations of the previously mentioned drugs in the body.

Some medicines called prodrugs become activated only after certain changes are made in the body. Some prodrugs are activated by the enzyme CYP2D6, like codeine which is transformed in the body into morphine for analgesia.

Pharmacodynamics :

Pharmacodynamics focuses on how a drug affects the body, including both its therapeutic effects and any side effects that may arise. Interestingly, genomic factors can also play a role in pharmacodynamics; for instance, certain gene variants are linked to a higher risk of serious adverse reactions. Take carbamazepine, a powerful medication for epilepsy. There's a gene variant called HLA-B*15:02 that raises the risk of severe hypersensitivity reactions, which can lead to serious conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis—both of which can be life-threatening.

However, screening for this variant isn't a straightforward solution. Professor Dyfrig Hughes from the Centre for Health Economics and Medicines Evaluation at Bangor University highlighted this at Maya’s pharmacogenomics event. He pointed out that if all patients with this gene variant were switched to a different medication, the outcome could be concerning: for every hypersensitivity reaction prevented, about three patients might end up with uncontrolled epilepsy because the alternative drug isn’t as effective. This means that clinicians and patients need to carefully consider the risks involved.



Personalizing Disease Prevention :

The idea of using historical news to create effective prevention strategies for diseases is already well recognized in controlled environments, but it hasn't quite made its way into everyday practice yet. There are plenty of compelling examples showing how tapping into ancestral knowledge can help reduce the risk of illness and lower barriers in standard treatment and screening methods. A classic case is colorectal cancer, which is the third leading cause of cancer deaths, even though it's highly preventable. In 2012, Liao and colleagues found that patients who took aspirin and had a specific mutation in the PIK3CA gene in their colorectal cancers had better overall survival rates and a lower risk of cancer-specific death compared to those whose cancers had the normal PIK3CA gene.

Improving cancer treatment :

Breast tumors are treated with medications and sometimes a destructive agent, and occasionally, the disease can be detected through imaging. For instance, tamoxifen is the go-to drug for patients with estrogen receptor-positive breast cancer that hasn't spread to the lymph nodes, while a destructive agent is also used in certain cases. However, this agent tends to only help a select group of patients. In fact, a long-term study known as the National Surgical Adjuvant Breast and Bowel Project (NSABP) found that only 4% of patients who received this treatment saw improved outcomes (Paik et al., 2004). The answer to this question seems to be "yes." For example, the NSABP research team used original occasion PCR to analyze gene expression in tumors and developed a diagnostic kit that identified 21 genes using large paraffin-embedded samples (Paik et al., 2004). This research has led to diagnostic tools that can pinpoint significant genetic factors in tumors for specific patients and improve treatment outcomes. These diagnostic tools can assess the likelihood of tumors in low-, intermediate-, and high-risk patients. In clinical trials, the data showed overall improvement (Paik et al., 2006). Additionally, in the study to determine treatment, researchers examined tissue from the original NSABP study. They found no benefit in adding a medication to tamoxifen for low-risk patients and only a slight benefit (2%) for intermediate-risk patients. However, the advantages of treatment were evident in high-risk patients, with a 28% reduction in cancer occurrence.

Early Examples of Personalized Medicine :

There have existed an excellent many examples of interferences tailor-made to individual patient characterizations, virtually all of ruling class established historical profiles. Before providing any classic instances, it concedes possibility be emphasized that embodied cure maybe practiced not only for the situation of ailment, but likewise for the early detection and stop of affliction. We supply some factual instances of embodied disease situations present and deem early detection and stop in the next division, as growths in embodied disease discovery and stop are much more current.



Many early instances of embodied cures were associated with innately-interceded pharmacokinetic facets of drugs. This was due incompletely to the biomedical wisdom society's understanding of drug metabolizing enzymes and the role they play in the physique's answer to drugs. A superior initiation to pharmacogenetic features of drugs, as well ancestral modifications in genes that influence the efficiency and reactions of drugs (exceptionally concerning genetic variations in drug metabolizing enzymes) is procedure by Weber. Warfarin is a usual ancestry irrigating medication that, except that drug correctly, take care of cause a conceivably mortal adverse drug backlash. Warfarin aims the deoxyribonucleic acid, VKORC1, and is metabolized incompletely by the deoxyribonucleic acid CYP2C9. Naturally-happening ancestral difference in two together the VKORC1 and CYP2C9 genes leads to variation in the pharmacodynamic and pharmacokinetic characteristics of Warfarin across things, eventually devising difference in things' responses to warfarin. The US Food and Drug Administration has accordingly urged that drug for warfarin include an individual's genotype (that is, the dose must be embodied to an individual established the particular hereditary modifications they maintain in the VKORC1 and CYP2C9 genes).

A final, frequently-named instance of an embodied cure is the drug imatinib. Imatinib is used to treat chronic myelogenous leukemia (CML). Imatinib restricts a catalyst, tyrosine kinase, that is to say raised for one establishment of a fusion of two genomic domains, individual including the Abelson proto-oncogene (abl) and the different the breakpoint cluster domain (bcr). This fusion occurrence stands in many tumors donating to the incident of

CML and is refer to as the 'bcr-abl mixture' or 'Philadelphia chromosome.' However, not all things accompanying CML have tumors protecting the bcr-abl melding metamorphosis. Therefore, imatinib is typically likely only too individual CML cases at this moment melding occurrence.

Advantages :

Targeted Treatments:

One of the primary advantages of personalized medicine is the possibility to tailor treatments to each patient's specific needs.

As just by considering the individual's genetic makeup, doctors can create the most effective medications and therapies, thus, minimizing trial and error in treatment plans.

Prevention And Early Detection:

Personalized medicine enables early detection and prevention of diseases, through the use of genetic testing to detect an individual's predilection to certain diseases, and that in fact allows for proactive interventions and lifestyle modifications to prevent or delay the beginning of these conditions.

Patient Empowerment:

A well-prepared personalized medicine case study shows the impact of personalized medicine on active participants through their healthcare journey.

Patients who understand their genetic and environmental factors can make informed decisions about their lifestyle choices, treatment options, and disease management strategies.

Cost-Effective Healthcare:

Although personalized medicine requires an upfront investment in genetic testing and analysis, however, it has the potential to reduce health care costs in the long run.

Through identifying the most effective treatments, unnecessary or ineffective therapies can be avoided, which will lead to minimizing healthcare expenditures in one way or another.

Some other advantages:

New approaches for protecting research participants, particularly patients' privacy and the confidentiality of their data.

Improved ability to predict which treatments will work best for specific patients.

Better understanding of the underlying mechanisms by which various diseases occur.

Improved approaches to preventing, diagnosing, and treating a wide range of diseases.

Disadvantages

Limited Availability and Accessibility:

Personalized medicine is still in its early stages of development and implementation, moreover, cannot be something that is usable in a remote situation. That is why not all healthcare facilities have access to the required infrastructure, knowledge, and technological advancements required for personalized medicine.

Ethical and Privacy Concerns:

This is a huge red flag in the world of personalized medicine and medicine in general, as personalized medicine relies heavily on genetic data and personal information to function, raising concerns about privacy and potential misuse.

Therefore, protecting this data from unauthorized access and ensuring ethical practices in its usage become critical considerations in the implementation of personalized medicine.

Complex Regulatory Landscape:

Personalized medicine presents unique regulatory challenges, due to the nature of personalized treatments, which may involve the growth of new drugs or diagnostic tools, that require robust and flexible regulations to support innovation while ensuring patient safety.

Expensive and Time-consuming:

For sure implementing personalized medicine involves various processes, including genetic testing, data analysis, and treatment customization, and these procedures come with an expensive cost and time-consuming, limiting their accessibility to a large section of the population.

Conclusion:

In summary, the studies inspected in this place book demonstrate the potential of new microscopic approaches, containing multilogues genotyping, precious variant sequencing, and epigenetic signs, to identify hereditary cause of interindividual alternative in drug fighting in many important dispassionate districts, to a degree feelings cancer, leukemia, and lymphoma. The unification of multilayered drug dossier, containing deoxyribonucleic acid verbalization and drug target alterations, and pharmacokinetic descriptions acquired utilizing new forms and bioinformatics, has the potential to define drug exercise potential of various sufferers and, if secondhand effectively, will aid in accuracy cure.

REFERENCES:

1. Pandey, A. and Gupta, S.P., 2024. Personalized Medicine:(A Comprehensive Review). *Oriental Journal of Chemistry*, *40*(4).
2. Goetz, L.H. and Schork, N.J., 2018. Personalized medicine: motivation, challenges, and progress. *Fertility and sterility*, *109*(6), pp.952-963.
3. Cecchin, E. and Stocco, G., 2020. Pharmacogenomics and personalized medicine. *Genes*, *11*(6), p.679.
4. Singh, D.B., 2020. The impact of pharmacogenomics in personalized medicine. *Current Applications of Pharmaceutical Biotechnology*, pp.369-394.

5. Sadee, W., Wang, D., Hartmann, K., Toland, A.E. and Jeong, H., 2023. Pharmacogenomics: driving personalized medicine. *Pharmacological reviews*, *75*(4), pp.789-814.
6. McMahon, F.J. and Insel, T.R., 2012. Pharmacogenomics and personalized medicine in neuropsychiatry. *Neuron*, *74*(5), pp.773-776.
7. Mathur, S. and Sutton, J., 2017. Personalized medicine could transform healthcare. *Biomedical reports*, *7*(1), pp.3-5.
8. Ashley, E.A., 2015. The precision medicine initiative: a new national effort. *Jama*, *313*(21), pp.2119-2120.
9. Khoury, M.J., Burke, W. and Thomson, E.J., 2005, June. Personalized medicine USA: pros, cons, but no way back. In *Workshop Abstracts* (Vol. 2, No. 2, p. 172).
10. Cecchin, E. and Stocco, G., 2020. Pharmacogenomics and personalized medicine. *Genes*, *11*(6), p.679.
11. Zhou, K., Pedersen, H.K., Dawed, A.Y. and Pearson, E.R., 2016. Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. *Nature Reviews Endocrinology*, *12*(6), pp.337-346.